Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)50% (Hyper Growth)
EST. PRICE IN 2031
$223.08
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$138.52
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.0x Exit PE.
Valuation Analysis: MMM is currently trading at $176.28, which is considered extended relative to its 30-day fair value range of $157.30 to $172.54. The stock's valuation (Forward PE: 18.2) is in line with its historical norms (17.0). At these levels, the market is pricing in 2.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MMM is in a strong uptrend. Immediate support is located at $159.01, while resistance sits at $184.90.
Market Sentiment: MMM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$157.30 -
$172.54
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding MMM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.
